Oncothyreon Stock Hits New 52-Week Low (ONTY)

NEW YORK ( TheStreet) -- Oncothyreon (Nasdaq: ONTY) hit a new 52-week low Wednesday as it is currently trading at $3.93, below its previous 52-week low of $3.94 with 373,921 shares traded as of 3:16 p.m. ET. Average volume has been 1.2 million shares over the past 30 days.

Oncothyreon has a market cap of $229.1 million and is part of the health care sector and drugs industry. Shares are down 47.2% year to date as of the close of trading on Tuesday.

Oncothyreon Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic products for the treatment of cancer. Its primary product candidate, Stimuvax is in Phase III clinical trials for the treatment of non-small cell lung cancer.

TheStreet Ratings rates Oncothyreon as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity and poor profit margins. You can view the full Oncothyreon Ratings Report.

See all 52-week low stocks or get investment ideas from our investment research center.